Mathai Mammen, M.D., Ph.D., Leaves Position as Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson
August 08 2022 - 6:45PM
Business Wire
Johnson & Johnson (NYSE: JNJ) (“the Company”) announced
today that Mathai Mammen, M.D., Ph.D., has decided to leave his
position as Executive Vice President, Pharmaceuticals, R&D, and
pursue other opportunities outside of the Company. William Hait,
M.D., Ph.D., will serve as interim head of the Pharmaceutical
R&D organization until new leadership is identified.
Dr. Mammen joined Johnson & Johnson in 2017 as Global Head
of Janssen R&D, and the Company thanks Dr. Mammen for his
contributions in advancing Johnson & Johnson’s industry-leading
portfolio. The Company will continue to prioritize innovation and
building new capabilities to improve the lives of the patients and
consumers we serve worldwide.
About Johnson & Johnson
At Johnson & Johnson, we believe good health is the
foundation of vibrant lives, thriving communities and forward
progress. That's why for more than 130 years, we have aimed to keep
people well at every age and every stage of life. Today, as the
world's largest and most broadly-based health care company, we are
committed to using our reach and size for good. We strive to
improve access and affordability, create healthier communities, and
put a healthy mind, body and environment within reach of everyone,
everywhere. We are blending our heart, science and ingenuity to
profoundly change the trajectory of health for humanity.
Cautions Concerning Forward Looking Statements
This press release contains "forward-looking statements" as
defined in the Private Securities Litigation Reform Act of 1995.
The reader is cautioned not to rely on these forward-looking
statements. These statements are based on current expectations of
future events. If underlying assumptions prove inaccurate or known
or unknown risks or uncertainties materialize, actual results could
vary materially from the expectations and projections of Johnson
& Johnson. A list and descriptions of risks, uncertainties and
other factors can be found in Johnson & Johnson's Annual Report
on Form 10-K for the fiscal year ended January 2, 2022, including
in the sections captioned "Cautionary Note Regarding
Forward-Looking Statements" and "Item 1A. Risk Factors," and in the
Company's subsequent Quarterly Reports on Form 10-Q and other
filings with the Securities and Exchange Commission. Copies of
these filings are available online at www.sec.gov,www.jnj.com or on
request from Johnson & Johnson. Any forward-looking statement
made in this release speaks only as of the date of this release.
Johnson & Johnson does not undertake to update any
forward-looking statement as a result of new information or future
events or developments.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220808005842/en/
Press Contact: Jake Sargent (732) 524-1090 Investor
Contact: Jessica Moore (732) 524-2955
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024